{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:10:05Z","timestamp":1793211005768,"version":"4.5.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jcin.2024.08.022","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T14:48:43Z","timestamp":1728917323000},"page":"2197-2215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Antithrombotic Therapy in High Bleeding Risk, Part I"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-182X","authenticated-orcid":false,"given":"Mattia","family":"Galli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6943-278X","authenticated-orcid":false,"given":"Felice","family":"Gragnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Berteotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4395-6742","authenticated-orcid":false,"given":"Giuseppe","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1456-6430","authenticated-orcid":false,"given":"Felicita","family":"Andreotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-3968","authenticated-orcid":false,"given":"Giuseppe","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-574X","authenticated-orcid":false,"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Perrone Filardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plinio","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2024.08.022_bib1","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2024.08.022_bib2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/CIRCULATIONAHA.121.054305","article-title":"Antithrombotic therapy in patients undergoing transcatheter interventions for structural heart disease","volume":"144","author":"Calabr\u00f2","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.022_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvz036","volume":"6","author":"Savarese","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"8","key":"10.1016\/j.jcin.2024.08.022_bib4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.31083\/j.rcm2308286","article-title":"Bleeding complications in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib5","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.022_bib6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/pgs-2022-0057","article-title":"Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jcin.2024.08.022_bib7","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the Academic Research Consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.022_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.975969","article-title":"De-escalation of antiplatelet therapy in acute coronary syndromes: why, how and when?","volume":"9","author":"Galli","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib10","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMoa1500893","article-title":"Effect of availability of transcatheter aortic-valve replacement on clinical practice","volume":"373","author":"Rein\u00f6hl","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib11","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.022_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/ehjcvp\/pvz031","article-title":"Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis","volume":"6","author":"Galli","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jcin.2024.08.022_bib13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","article-title":"Comparative efficacy and safety of oral P2Y(12) inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials","volume":"142","author":"Navarese","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.022_bib14","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","article-title":"Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials","volume":"43","author":"Galli","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.022_bib15","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials","volume":"350","author":"Navarese","year":"2015","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.jcin.2024.08.022_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvaa001","article-title":"Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials","volume":"7","author":"Benenati","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jcin.2024.08.022_bib17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.022_bib18","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.022_bib19","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.08.022_bib20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jcin.2024.08.022_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/ehjcvp\/pvad063","article-title":"External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysis","volume":"9","author":"Munaf\u00f2","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jcin.2024.08.022_bib22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.022_bib23","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.4244\/EIJV16I14A202","article-title":"Consolidating the value of the standardised ARC-HBR definition","volume":"16","author":"Gargiulo","year":"2021","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2024.08.022_bib24","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1093\/eurheartj\/ehaa671","article-title":"Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk","volume":"41","author":"Corpataux","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.022_bib25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamacardio.2020.6814","article-title":"Assessing the risks of bleeding vs thrombotic events in patients at high bleeding risk after coronary stent implantation: the ARC-High Bleeding Risk Trade-off Model","volume":"6","author":"Urban","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tcm.2021.12.007","article-title":"Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention","volume":"33","author":"Galli","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2024.08.022_bib28","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.jcin.2021.07.016","article-title":"3- or 1-Month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation","volume":"14","author":"Mehran","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.009565","article-title":"One-month dual antiplatelet therapy following percutaneous coronary intervention with zotarolimus-eluting stents in high-bleeding-risk patients","volume":"13","author":"Kandzari","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib30","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib31","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/eurheartj\/ehac706","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials","volume":"44","author":"Costa","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.022_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvae057","article-title":"P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jcin.2024.08.022_bib33","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/17512433.2021.1927709","article-title":"Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations","volume":"14","author":"Galli","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jcin.2024.08.022_bib34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ehjcvp\/pvad085","article-title":"Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis","volume":"10","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"38","key":"10.1016\/j.jcin.2024.08.022_bib35","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.022_bib36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.022_bib37","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib38","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.123.013242","article-title":"Short-term DAPT and DAPT de-escalation strategies for patients with acute coronary syndromes: a systematic review and network meta-analysis","volume":"16","author":"Kuno","year":"2023","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib39","article-title":"International consensus statement on platelet function and genetic testing for guiding oral P2Y12 inhibitor treatment in percutaneous coronary intervention: 2024 update","author":"Angiolillo","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib40","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1093\/eurheartj\/ehac294","article-title":"Great debate: triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1\u00a0week","volume":"43","author":"De Caterina","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.022_bib41","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.022_bib42","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/europace\/euz345","volume":"22","author":"Galli","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.jcin.2024.08.022_bib43","article-title":"Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS\/PCI: a critical appraisal","volume":"28","author":"Galli","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.jcin.2024.08.022_bib44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ehjcvp\/pvz030","article-title":"Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared with triple therapy","volume":"6","author":"Galli","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jcin.2024.08.022_bib45","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.121.056680","article-title":"Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapy after coronary stenting: an open-label, randomized, controlled trial","volume":"144","author":"Smits","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.022_bib46","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.022_bib47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2020.05.024","article-title":"Commentary: Temporarily omitting oral anticoagulants early after stenting for acute coronary syndromes patients with atrial fibrillation","volume":"318","author":"Limbruno","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib48","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/CIRCULATIONAHA.119.044584","article-title":"Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial","volume":"141","author":"Lopes","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.022_bib49","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1056\/NEJMoa2101897","article-title":"Left atrial appendage occlusion during cardiac surgery to prevent stroke","volume":"384","author":"Whitlock","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib50","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jcin.2011.03.018","article-title":"Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry","volume":"4","author":"Brilakis","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib51","article-title":"Prior coronary artery bypass graft surgery and outcome after percutaneous coronary intervention: an observational study from the Pan-London Percutaneous Coronary Intervention Registry","volume":"9","author":"Rathod","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jcin.2024.08.022_bib52","doi-asserted-by":"crossref","first-page":"E785","DOI":"10.1002\/ccd.29935","article-title":"Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft","volume":"98","author":"Beerkens","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"issue":"5","key":"10.1016\/j.jcin.2024.08.022_bib53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41569-023-00953-4","article-title":"Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction","volume":"21","author":"Galli","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib54","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2024.08.022_bib55","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2012.09.014","article-title":"Discontinuation of long-term clopidogrel therapy is associated with death and myocardial infarction after saphenous vein graft percutaneous coronary intervention","volume":"60","author":"Sachdeva","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib56","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.4244\/EIJ-D-22-00319","article-title":"Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study","volume":"18","author":"Sardella","year":"2022","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2024.08.022_bib57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17512433.2023.2154651","article-title":"Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications","volume":"16","author":"Galli","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jcin.2024.08.022_bib58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jacc.2018.10.048","article-title":"Rivaroxaban, aspirin, or both to prevent early coronary bypass graft occlusion: the COMPASS-CABG study","volume":"73","author":"Lamy","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib59","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2337\/diabetes.48.6.1289","article-title":"Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial","volume":"48","author":"Hoogwerf","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.jcin.2024.08.022_bib60","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jacc.2022.11.050","article-title":"Bleeding events after transcatheter aortic valve replacement: JACC State-of-the-Art Review","volume":"81","author":"Avvedimento","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib61","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.jcin.2017.04.034","article-title":"Frequency, timing, and impact of access-site and non-access-site bleeding on mortality among patients undergoing transcatheter aortic valve replacement","volume":"10","author":"Piccolo","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib62","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1016\/j.jcin.2023.10.011","article-title":"Bleeding in patients undergoing transfemoral transcatheter aortic valve replacement: incidence, trends, clinical outcomes, and predictors","volume":"16","author":"van Nieuwkerk","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib63","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.jacc.2012.02.022","article-title":"Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted meta-analysis of 3,519 patients from 16 studies","volume":"59","author":"G\u00e9n\u00e9reux","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib64","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.jacc.2014.08.052","article-title":"Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement","volume":"64","author":"G\u00e9n\u00e9reux","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib65","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jcin.2020.01.238","article-title":"Frailty and bleeding in older adults undergoing TAVR or SAVR: insights from the FRAILTY-AVR study","volume":"13","author":"Bendayan","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib66","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1016\/j.jacc.2019.09.015","article-title":"Sex differences in transfemoral transcatheter aortic valve replacement","volume":"74","author":"Vlastra","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib67","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jcin.2017.07.044","article-title":"Association of chronic kidney disease with in-hospital outcomes of transcatheter aortic valve replacement","volume":"10","author":"Gupta","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib68","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2021.01.003","article-title":"Severity grading system for acute allergic reactions: a multidisciplinary Delphi study","volume":"148","author":"Dribin","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.jcin.2024.08.022_bib69","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/ehjacc\/zuad051","article-title":"The evaluation and management of coagulopathies in the intensive therapy units","volume":"12","author":"Galli","year":"2023","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.jcin.2024.08.022_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcin.2018.09.041","article-title":"Blood disorders in patients undergoing transcatheter aortic valve replacement: a review","volume":"12","author":"De Larochelli\u00e8re","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib71","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jcin.2015.02.008","article-title":"Treatment of acquired von Willebrand syndrome in aortic stenosis with transcatheter aortic valve replacement","volume":"8","author":"Spangenberg","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib72","doi-asserted-by":"crossref","first-page":"503","DOI":"10.4244\/EIJ-D-21-01048","article-title":"Bleeding risk differences after TAVR according to the ARC-HBR criteria: insights from SCOPE 2","volume":"18","author":"Garot","year":"2022","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2024.08.022_bib73","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jcin.2021.03.024","article-title":"Development and validation of a practical model to identify patients at risk of bleeding after TAVR","volume":"14","author":"Navarese","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib74","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4244\/EIJ-D-23-01020","article-title":"Defining high bleeding risk in patients undergoing transcatheter aortic valve implantation: a VARC-HBR consensus document","volume":"20","author":"Garot","year":"2024","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2024.08.022_bib75","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1093\/eurheartj\/ehaa542","article-title":"Leaflet immobility and thrombosis in transcatheter aortic valve replacement","volume":"41","author":"Ng","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.022_bib76","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","article-title":"Transcatheter versus surgical aortic-valve replacement in high-risk patients","volume":"364","author":"Smith","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib77","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa1400590","article-title":"Transcatheter aortic-valve replacement with a self-expanding prosthesis","volume":"370","author":"Adams","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib78","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","volume":"10","author":"Rod\u00e9s-Cabau","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib79","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without clopidogrel after transcatheter aortic-valve implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib80","article-title":"Aspirin alone versus dual antiplatelet therapy after transcatheter aortic valve implantation: a systematic review and patient-level meta-analysis","volume":"10","author":"Brouwer","year":"2021","journal-title":"J\u00a0Heart Assoc"},{"key":"10.1016\/j.jcin.2024.08.022_bib81","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacc.2020.11.035","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib82","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehab196","volume":"42","author":"Ten Berg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.022_bib83","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.010097","article-title":"Aspirin versus clopidogrel as single antithrombotic therapy after transcatheter aortic valve replacement: insight from the OCEAN-TAVI registry","volume":"14","author":"Kobari","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib84","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jacc.2022.11.041","article-title":"P2Y(12) inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions","volume":"81","author":"Gragnano","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib85","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y(12) inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib86","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcin.2018.10.005","article-title":"Assessment of platelet REACtivity after transcatheter aortic valve replacement: the REAC-TAVI trial","volume":"12","author":"Jimenez Diaz","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib87","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.amjcard.2021.05.047","article-title":"Comparison of ticagrelor versus clopidogrel on cerebrovascular microembolic events and platelet inhibition during transcatheter aortic valve implantation","volume":"154","author":"Vavuranakis","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib88","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A\u00a0controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib89","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.022_bib90","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.122.059512","article-title":"Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: the ADAPT-TAVR randomized clinical trial","volume":"146","author":"Park","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.022_bib91","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","article-title":"Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation","volume":"382","author":"Nijenhuis","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib92","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.jcin.2016.06.025","article-title":"Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement","volume":"9","author":"Abdul-Jawad Altisent","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib93","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jcin.2021.05.025","article-title":"TAVR patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist?","volume":"14","author":"Didier","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib94","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib95","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.123.067312","article-title":"Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation","volume":"149","author":"Kapadia","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.022_bib96","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pcad.2022.05.007","article-title":"Hypoattenuated leaflet thickening (HALT) and reduced leaflet motion (RELM) of aortic bioprostheses: an imaging finding or a complication?","volume":"72","author":"Ahmad","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jcin.2024.08.022_bib97","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1911426","article-title":"Reduced leaflet motion after transcatheter aortic-valve replacement","volume":"382","author":"De Backer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib98","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/heartjnl-2023-322946","article-title":"Impact of leaflet thrombosis on valve haemodynamic status after transcatheter aortic valve replacement","volume":"110","author":"Jang","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.jcin.2024.08.022_bib99","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jcin.2022.04.018","article-title":"Long-term follow-up of hypoattenuated leaflet thickening after transcatheter aortic valve replacement","volume":"15","author":"Hein","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib100","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.006730","article-title":"Clinical valve thrombosis after transcatheter aortic valve-in-valve implantation","volume":"11","author":"Abdel-Wahab","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib101","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4244\/EIJ-D-17-00493","article-title":"Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical\/echocardiographic data from a global prospective observational study","volume":"13","author":"Landmesser","year":"2017","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2024.08.022_bib102","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.hrthm.2023.01.007","article-title":"SCAI\/HRS expert consensus statement on transcatheter left atrial appendage closure","volume":"20","author":"Saw","year":"2023","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jcin.2024.08.022_bib103","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jcin.2015.08.035","article-title":"Bleeding outcomes after left atrial appendage closure compared with long-term warfarin: a pooled, patient-level analysis of the WATCHMAN randomized trial experience","volume":"8","author":"Price","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib104","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.120.050117","article-title":"Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial","volume":"143","author":"Kar","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.022_bib105","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1161\/CIRCULATIONAHA.121.057063","article-title":"Amplatzer Amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial","volume":"144","author":"Lakkireddy","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.022_bib106","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jcin.2022.02.009","article-title":"Clinical outcomes at 1 year following transcatheter left atrial appendage occlusion in the United States","volume":"15","author":"Price","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib107","doi-asserted-by":"crossref","first-page":"774","DOI":"10.4244\/EIJ-D-20-01309","article-title":"Incidence and clinical impact of major bleeding following left atrial appendage occlusion: insights from the Amplatzer Amulet Observational Post-Market Study","volume":"17","author":"Aminian","year":"2021","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2024.08.022_bib108","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jacep.2023.02.007","article-title":"Left atrial appendage occlusion in the elderly: insights from PROTECT-AF, PREVAIL, and continuous access registries","volume":"9","author":"Sulaiman","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib109","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacc.2021.04.098","article-title":"Predictors of device-related thrombus following percutaneous left atrial appendage occlusion","volume":"78","author":"Simard","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib110","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jacc.2020.11.046","article-title":"Prognostic implications of declining hemoglobin content in patients hospitalized with acute coronary syndromes","volume":"77","author":"Leonardi","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib111","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.122.012812","article-title":"Antithrombotic management after left atrial appendage closure: current evidence and future perspectives","volume":"16","author":"Mesnier","year":"2023","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib112","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.08.022_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib114","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jacc.2019.09.064","article-title":"Long-term safety and efficacy in continued access left atrial appendage closure registries","volume":"74","author":"Holmes","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib115","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.jcin.2021.07.031","article-title":"Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion","volume":"14","author":"Della Rocca","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib116","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008481","article-title":"Reduced rivaroxaban dose versus dual antiplatelet therapy after left atrial appendage closure: ADRIFT a randomized pilot study","volume":"13","author":"Duthoit","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib117","doi-asserted-by":"crossref","first-page":"e1038","DOI":"10.4244\/EIJ-D-22-00627","article-title":"Left atrial appendage occlusion","volume":"18","author":"Holmes","year":"2023","journal-title":"EuroIntervention"},{"issue":"11","key":"10.1016\/j.jcin.2024.08.022_bib118","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jcin.2023.01.011","article-title":"SCAI\/HRS expert consensus statement on transcatheter left atrial appendage closure","volume":"16","author":"Saw","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib119","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2022.02.047","article-title":"Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fibrillation","volume":"79","author":"Freeman","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib120","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2362.2011.02594.x","article-title":"Justification of 150\u00a0mg clopidogrel in patients with high on-clopidogrel platelet reactivity","volume":"42","author":"Aradi","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jcin.2024.08.022_bib121","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4244\/EIJ-D-17-00042","article-title":"Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry","volume":"13","author":"Bergmann","year":"2017","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2024.08.022_bib122","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jcin.2019.04.004","article-title":"Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with WATCHMAN","volume":"12","author":"S\u00f8ndergaard","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.022_bib123","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/eurheartj\/ehaa169","article-title":"Left atrial appendage occlusion with the Amplatzer\u2122 Amulet\u2122 device: full results of the prospective global observational study","volume":"41","author":"Hildick-Smith","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.022_bib124","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.hrthm.2017.05.038","article-title":"Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial","volume":"14","author":"Boersma","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jcin.2024.08.022_bib125","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.4244\/EIJ-D-18-00344","article-title":"Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry","volume":"14","author":"Landmesser","year":"2018","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2024.08.022_bib126","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.amjcard.2020.08.013","article-title":"Safety and efficacy of single versus dual antiplatelet therapy after left atrial appendage occlusion","volume":"134","author":"Patti","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2024.08.022_bib127","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.022_bib128","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2300525","article-title":"Transcatheter repair for patients with tricuspid regurgitation","volume":"388","author":"Sorajja","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib129","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1009355","article-title":"Percutaneous repair or surgery for mitral regurgitation","volume":"364","author":"Feldman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib130","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.022_bib131","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.07.049","article-title":"Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation","volume":"108(12)","author":"Ussia","year":"2011","journal-title":"Am J Cardiol"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879824011099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879824011099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T19:44:08Z","timestamp":1734637448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879824011099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":131,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1936879824011099"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2024.08.022","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Therapy in High Bleeding Risk, Part I","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2024.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}